Shanghai Henlius Biotech FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion

Reuters03-20 18:17

<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion

Henlius published an annual results announcement for the year ended 31 December 2025 under IFRS Accounting Standards.
Total revenue rose 16.5% to RMB6.67 billion, driven mainly by drug sales, R&D services provided to customers, and license income.
R&D expenditure increased to RMB2.49 billion, including expensed R&D expenses of RMB1.52 billion.
Total profit was RMB827 million, up 0.79%, which Henlius attributed mainly to higher sales volumes of core products, growth in overseas commercialization profit, and expanded clinical activities.
The board did not recommend a final dividend.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12060899), on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620237782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620237782","market":"nz","top_or_hot":-1,"title":"Shanghai Henlius Biotech FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> FY2025 revenue rose 16.5% to RMB6.67 billion, R&amp;D expenditure jumped 35.4% to RMB2.49 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Henlius published an annual results announcement for the year ended 31 December 2025 under IFRS Accounting Standards.\n        </li>\n<li>\n          Total revenue rose 16.5% to RMB6.67 billion, driven mainly by drug sales, R&amp;D services provided to customers, and license income.\n        </li>\n<li>\n          R&amp;D expenditure increased to RMB2.49 billion, including expensed R&amp;D expenses of RMB1.52 billion.\n        </li>\n<li>\n          Total profit was RMB827 million, up 0.79%, which Henlius attributed mainly to higher sales volumes of core products, growth in overseas commercialization profit, and expanded clinical activities.\n        </li>\n<li>\n          The board did not recommend a final dividend.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12060899), on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius Biotech FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius Biotech FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 18:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> FY2025 revenue rose 16.5% to RMB6.67 billion, R&amp;D expenditure jumped 35.4% to RMB2.49 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Henlius published an annual results announcement for the year ended 31 December 2025 under IFRS Accounting Standards.\n        </li>\n<li>\n          Total revenue rose 16.5% to RMB6.67 billion, driven mainly by drug sales, R&amp;D services provided to customers, and license income.\n        </li>\n<li>\n          R&amp;D expenditure increased to RMB2.49 billion, including expensed R&amp;D expenses of RMB1.52 billion.\n        </li>\n<li>\n          Total profit was RMB827 million, up 0.79%, which Henlius attributed mainly to higher sales volumes of core products, growth in overseas commercialization profit, and expanded clinical activities.\n        </li>\n<li>\n          The board did not recommend a final dividend.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12060899), on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00656","symbol_name":"复星国际","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL5QgkLK:1","article_id":"2620237782","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620237782","pubTimestamp":1774001863,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Henlius published an annual results announcement for the year ended 31 December 2025 under IFRS Accounting Standards.Total revenue rose 16.5% to RMB6.67 billion, driven mainly by drug sales, R&D services provided to customers, and license income.R&D expenditure increased to RMB2.49 billion, including expensed R&D expenses of RMB1.52 billion.Total profit was RMB827 million, up 0.79%, which Henlius attributed mainly to higher sales volumes of core products, growth in overseas commercialization profit, and expanded clinical activities.The board did not recommend a final dividend.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00656":"复星国际","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1230":"工业集团企业","02696":"复宏汉霖","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1161":"生物科技"},"translate_title":"上海复宏汉霖生物2025财年收入增长16.5%至人民币66.7亿元，研发支出增长35.4%至人民币24.9亿元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00656":0.9,"02696":0.9},"content_text":"Shanghai Henlius Biotech FY2025 revenue rose 16.5% to RMB6.67 billion, R&D expenditure jumped 35.4% to RMB2.49 billion\n    \n\n\n          Henlius published an annual results announcement for the year ended 31 December 2025 under IFRS Accounting Standards.\n        \n\n          Total revenue rose 16.5% to RMB6.67 billion, driven mainly by drug sales, R&D services provided to customers, and license income.\n        \n\n          R&D expenditure increased to RMB2.49 billion, including expensed R&D expenses of RMB1.52 billion.\n        \n\n          Total profit was RMB827 million, up 0.79%, which Henlius attributed mainly to higher sales volumes of core products, growth in overseas commercialization profit, and expanded clinical activities.\n        \n\n          The board did not recommend a final dividend.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12060899), on March 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620237782","isCrawlerRequest":true}